Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company whose news flow centers on the treatment and prevention of cancer. Company announcements frequently highlight progress in its ovarian cancer immunotherapy program and its portfolio of cancer vaccines, especially an investigational breast cancer vaccine developed in collaboration with Cleveland Clinic.
News items for ANIX often cover clinical trial milestones, such as completion of a Phase 1 trial, presentation of final data at major scientific meetings, and plans to advance programs into subsequent phases of development. For the breast cancer vaccine targeting α-lactalbumin, disclosures have included safety and immune response findings, details on trial cohorts, and steps to transfer the related IND sponsorship from Cleveland Clinic to Anixa for future trials.
Another recurring theme in Anixa’s news is its ovarian cancer CER-T (CAR-T) program, including regulatory and naming milestones. The company has reported that the World Health Organization’s International Nonproprietary Names Expert Committee approved “liraltagene autoleucel” (lira-cel) as the non-proprietary name for its FSHR-targeted CAR-T therapy, and updates often describe the ongoing first-in-human trial in recurrent ovarian cancer.
Investors and observers can also expect intellectual property updates, such as U.S. and international patent issuances that extend protection for the breast cancer vaccine technology, as well as participation in investor conferences and research-focused fireside chats. Together, these news items provide insight into Anixa’s clinical progress, collaboration activities with institutions like Cleveland Clinic and Moffitt Cancer Center, and the evolution of its immuno-oncology pipeline.
Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering its breast cancer vaccine technology. The patent, exclusively licensed from Cleveland Clinic, provides composition-of-matter protection for their novel immunogenic approach in Canada.
The vaccine targets human α-lactalbumin, a protein expressed during lactation and in certain breast cancers. This technology addresses a significant market need, as breast cancer represents 25% of new cancer cases in Canadian women and 13% of female cancer deaths annually. The patent strengthens Anixa's international intellectual property portfolio and supports future regulatory and commercial efforts outside the U.S.
Anixa Biosciences (NASDAQ: ANIX) has been awarded U.S. Patent Number 12,370,244, extending protection for its breast cancer vaccine technology into the mid-2040s. The patent covers novel immunization methods using human α-lactalbumin protein, which is expressed during lactation and in certain breast cancers.
Developed in collaboration with Cleveland Clinic, this vaccine represents a pioneering approach to breast cancer prevention, targeting a significant unmet need. With 297,000 new cases of invasive breast cancer projected in 2025 and 43,000 expected deaths in the U.S., the technology addresses a potential multi-billion dollar market opportunity, particularly for women at risk of triple-negative breast cancer (TNBC).
Anixa Biosciences (NASDAQ: ANIX) announced the upcoming issuance of U.S. Patent Number 12,357,593 on July 15, 2025, strengthening its intellectual property portfolio for ovarian cancer vaccine technology. The patent covers methods of eliciting immune responses targeting anti-Müllerian hormone receptor, type II (AMHR2), a key target for ovarian cancer prevention and treatment.
The vaccine technology, developed in collaboration with Cleveland Clinic and the National Cancer Institute, focuses on preventing and treating ovarian cancer, particularly in high-risk populations with BRCA mutations or family history. The patent, issued to Cleveland Clinic with Anixa holding worldwide rights, includes methods for administering immunogenic compositions comprising nucleic acid encoding AMHR2 polypeptide.
FAQ
What is the current stock price of Anixa Biosciences (ANIX)?
What is the market cap of Anixa Biosciences (ANIX)?
